Literature DB >> 31997571

A Biomimetic Tumor Model of Heterogeneous Invasion in Pancreatic Ductal Adenocarcinoma.

Michael J Bradney1, Stephanie M Venis1, Yi Yang2, Stephen F Konieczny2, Bumsoo Han1.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a complex, heterogeneous, and genetically unstable disease. Its tumor microenvironment (TME) is complicated by heterogeneous cancer cell populations and strong desmoplastic stroma. This complex and heterogeneous environment makes it challenging to discover and validate unique therapeutic targets. Reliable and relevant in vitro PDAC tumor models can significantly advance the understanding of the PDAC TME and may enable the discovery and validation of novel drug targets. In this study, an engineered tumor model is developed to mimic the PDAC TME. This biomimetic model, named ductal tumor-microenvironment-on-chip (dT-MOC), permits analysis and experimentation on the epithelial-mesenchymal transition (EMT) and local invasion with intratumoral heterogeneity. This dT-MOC is a microfluidic platform where a duct of murine genetically engineered pancreatic cancer cells is embedded within a collagen matrix. The cancer cells used carry two of the three mutations of KRAS, CDKN2A, and TP53, which are key driver mutations of human PDAC. The intratumoral heterogeneity is mimicked by co-culturing these cancer cells. Using the dT-MOC model, heterogeneous invasion characteristics, and response to transforming growth factor-beta1 are studied. A mechanism of EMT and local invasion caused by the interaction between heterogeneous cancer cell populations is proposed.
© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  cancer cell invasion; epithelial-mesenchymal transition; intratumoral heterogeneity; microfluidic tumor models; pancreatic ductal adenocarcinoma

Mesh:

Year:  2020        PMID: 31997571      PMCID: PMC7069790          DOI: 10.1002/smll.201905500

Source DB:  PubMed          Journal:  Small        ISSN: 1613-6810            Impact factor:   13.281


  62 in total

Review 1.  Biomarkers for epithelial-mesenchymal transitions.

Authors:  Michael Zeisberg; Eric G Neilson
Journal:  J Clin Invest       Date:  2009-06-01       Impact factor: 14.808

Review 2.  In vitro microfluidic models of tumor microenvironment to screen transport of drugs and nanoparticles.

Authors:  Altug Ozcelikkale; Hye-Ran Moon; Michael Linnes; Bumsoo Han
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-02-14

Review 3.  Pancreatic adenocarcinoma.

Authors:  David P Ryan; Theodore S Hong; Nabeel Bardeesy
Journal:  N Engl J Med       Date:  2014-09-11       Impact factor: 91.245

4.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer.

Authors:  Peter J Campbell; Shinichi Yachida; Laura J Mudie; Philip J Stephens; Erin D Pleasance; Lucy A Stebbings; Laura A Morsberger; Calli Latimer; Stuart McLaren; Meng-Lay Lin; David J McBride; Ignacio Varela; Serena A Nik-Zainal; Catherine Leroy; Mingming Jia; Andrew Menzies; Adam P Butler; Jon W Teague; Constance A Griffin; John Burton; Harold Swerdlow; Michael A Quail; Michael R Stratton; Christine Iacobuzio-Donahue; P Andrew Futreal
Journal:  Nature       Date:  2010-10-28       Impact factor: 49.962

Review 5.  The role of stroma in pancreatic cancer: diagnostic and therapeutic implications.

Authors:  Mert Erkan; Simone Hausmann; Christoph W Michalski; Alexander A Fingerle; Martin Dobritz; Jörg Kleeff; Helmut Friess
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-06-19       Impact factor: 46.802

6.  Pancreatic cancer stroma: friend or foe?

Authors:  Jesse Gore; Murray Korc
Journal:  Cancer Cell       Date:  2014-06-16       Impact factor: 31.743

Review 7.  Tumour heterogeneity and resistance to cancer therapies.

Authors:  Ibiayi Dagogo-Jack; Alice T Shaw
Journal:  Nat Rev Clin Oncol       Date:  2017-11-08       Impact factor: 66.675

8.  Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.

Authors:  Ling Huang; Audrey Holtzinger; Ishaan Jagan; Michael BeGora; Ines Lohse; Nicholas Ngai; Cristina Nostro; Rennian Wang; Lakshmi B Muthuswamy; Howard C Crawford; Cheryl Arrowsmith; Steve E Kalloger; Daniel J Renouf; Ashton A Connor; Sean Cleary; David F Schaeffer; Michael Roehrl; Ming-Sound Tsao; Steven Gallinger; Gordon Keller; Senthil K Muthuswamy
Journal:  Nat Med       Date:  2015-10-26       Impact factor: 53.440

9.  Tubeless microfluidic angiogenesis assay with three-dimensional endothelial-lined microvessels.

Authors:  Lauren L Bischel; Edmond W K Young; Brianah R Mader; David J Beebe
Journal:  Biomaterials       Date:  2012-11-26       Impact factor: 12.479

10.  Pancreatic cancer stromal biology and therapy.

Authors:  Dacheng Xie; Keping Xie
Journal:  Genes Dis       Date:  2015-06-01
View more
  5 in total

1.  Engineering of a functional pancreatic acinus with reprogrammed cancer cells by induced PTF1a expression.

Authors:  Stephanie M Venis; Hye-Ran Moon; Yi Yang; Sagar M Utturkar; Stephen F Konieczny; Bumsoo Han
Journal:  Lab Chip       Date:  2021-09-28       Impact factor: 7.517

2.  A Cancer Cell Cluster Marked by LincRNA MEG3 Leads Pancreatic Ductal Adenocarcinoma Metastasis.

Authors:  Hong Pan; Huanrong Diao; Wen Zhong; Taifang Wang; Ping Wen; Chunli Wu
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

3.  An engineered pancreatic cancer model with intra-tumoral heterogeneity of driver mutations.

Authors:  Hye-Ran Moon; Altug Ozcelikkale; Yi Yang; Bennett D Elzey; Stephen F Konieczny; Bumsoo Han
Journal:  Lab Chip       Date:  2020-09-10       Impact factor: 7.517

Review 4.  Microfluidic Platforms for High-Throughput Pancreatic Ductal Adenocarcinoma Organoid Culture and Drug Screening.

Authors:  Marlene Geyer; Karla Queiroz
Journal:  Front Cell Dev Biol       Date:  2021-12-23

5.  Patient-derived pancreatic cancer-on-a-chip recapitulates the tumor microenvironment.

Authors:  Muhammad R Haque; Caitlin R Wessel; Daniel D Leary; Chengyao Wang; Abhinav Bhushan; Faraz Bishehsari
Journal:  Microsyst Nanoeng       Date:  2022-03-31       Impact factor: 7.127

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.